Atlas

Atlas Lithium Secures US$ 30,000,000 Strategic Investment and Offtake Agreement from Mitsui

Retrieved on: 
Thursday, March 28, 2024
Lithium, EV, Today, Goldman Sachs, Atlas, Partnership, Sale, Security (finance), Mineral, Investment, Memorandum of understanding, VWAP, DLA Piper, Corporation

The Strategic Investment provides Atlas Lithium with immediately available funds to continue its rapid development towards revenue generation with the production and sale of high-quality, low cost, environmentally sustainable lithium concentrate.

Key Points: 
  • The Strategic Investment provides Atlas Lithium with immediately available funds to continue its rapid development towards revenue generation with the production and sale of high-quality, low cost, environmentally sustainable lithium concentrate.
  • The Strategic Investment is a culmination of the mutual interest in growing Atlas Lithium.
  • Mitsui's investment reflects confidence in our team, assets, and business model," stated Marc Fogassa, CEO and Chairman of Atlas Lithium.
  • I have watched the relationship of our companies grow and I believe that this partnership with Mitsui strengthens Atlas Lithium substantially."

Renowned Lithium Executive Brian Talbot to Join Atlas Lithium as Chief Operating Officer and Director

Retrieved on: 
Thursday, March 21, 2024
Lithium, Culture, Atlas, University, Ravensthorpe, Galaxy Resources, Galaxy, Chemical engineering, Creativity, Mining

Mr. Talbot is a renowned lithium sector executive with extensive development and operational expertise.

Key Points: 
  • Mr. Talbot is a renowned lithium sector executive with extensive development and operational expertise.
  • Most recently, Mr. Talbot was founder and director of RTEK International DMCC, a consulting firm that advises lithium developers and producers.
  • From July 2022 to September 2023, Mr. Talbot was the Chief Operating Officer at Sigma Lithium Corporation ("Sigma Lithium"), a Canadian lithium producer with operations in Brazil.
  • "When speaking with global lithium investors, Brian Talbot is a name that is clearly revered as a ticket for success.

NGM Bio Announces Closing of Tender Offer

Retrieved on: 
Friday, April 5, 2024
Atlas, Patient, SAN, NGM, Column, Sub, Expiration, Guggenheim Partners, Therapy, Mergers and acquisitions, TCG, Holding company

The tender offer and related withdrawal rights expired at one minute after 11:59 p.m. Eastern Time on April 4, 2024 (the “Expiration Date”).

Key Points: 
  • The tender offer and related withdrawal rights expired at one minute after 11:59 p.m. Eastern Time on April 4, 2024 (the “Expiration Date”).
  • As of the Expiration Date, a total of 22,323,295 shares of NGM Bio common stock were validly tendered, and not validly withdrawn, representing approximately 27% of the outstanding shares of NGM Bio common stock as of the Expiration Date.
  • As of the Expiration Date, the number of shares validly tendered in accordance with the terms of the tender offer and not validly withdrawn satisfied the minimum tender condition, and all other conditions to the tender offer were satisfied or waived.
  • Following the closing of the tender offer, Merger Sub merged with and into NGM Bio and all shares of NGM Bio common stock that had not been validly tendered (other than shares held by stockholders who properly demanded appraisal of such shares or shares held by affiliates of TCG and certain other stockholders who agreed to exchange their shares for shares of Parent) were converted into the right to receive the Offer Price (the “Merger”).

Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseases

Retrieved on: 
Wednesday, April 3, 2024
Hereditary hemorrhagic telangiectasia, Telangiectasia, Biotechnology, Blood, Disease, Atlas, Patient, Lung, Stroke, Viking Global Investors, Death, Artery, Chiari malformation, Rupture, Intraparenchymal hemorrhage, Heart failure, Lightspeed Venture Partners, Therapy, TGF, Antibody, Bleeding, Heart, Pharmacology, Unified school district, HHT, PAH, Atlas Venture, Pulmonary hypertension, Pharmaceutical industry

CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies, launched today with $128 million in financing. The Series A was co-led by BVF Partners and Atlas Venture, with participation from Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors, Velosity Capital, and Checkpoint Capital. Diagonal was co-founded by Chief Executive Officer, Alex Lugovskoy, Ph.D., and Atlas and previously seeded by Atlas, Lightspeed Venture Partners, and Velosity Capital. The financing will support further advancement of the company’s proprietary DIAGONAL platform and pipeline of novel therapeutics to value-creating milestones, including its lead program for the treatment of hereditary hemorrhagic telangiectasia (HHT), a severely debilitating bleeding disorder with limited therapeutic options, through clinical proof-of-concept. Diagonal's agonist antibody activates a receptor complex in the TGF-β superfamily genetically impaired in HHT patients. In preclinical models of HHT, Diagonal's agonist antibodies prevent and reverse the formation of pathological vascular malformations.

Key Points: 
  • Diagonal was co-founded by Alex Lugovskoy, Ph.D., and Atlas and previously seeded by Atlas, Lightspeed Venture Partners, and Velosity Capital.
  • CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies, launched today with $128 million in financing.
  • Diagonal was co-founded by Chief Executive Officer, Alex Lugovskoy, Ph.D., and Atlas and previously seeded by Atlas, Lightspeed Venture Partners, and Velosity Capital.
  • In preclinical models of HHT, Diagonal's agonist antibodies prevent and reverse the formation of pathological vascular malformations.

Atlas Air and YunExpress Expand Strategic Partnership with Second Boeing 777-200 Freighter

Retrieved on: 
Thursday, March 28, 2024
Growth, Atlas, Partnership, Boeing, Aviation, Transport, Atlas Air, Atmosphere of Earth, Boeing 777, Airline

WHITE PLAINS, N.Y., March 28, 2024 (GLOBE NEWSWIRE) -- Atlas Air Inc., a subsidiary of Atlas Air Worldwide Holdings, Inc., a leading global provider of outsourced aviation logistics, today announced the expansion of its strategic partnership with YunExpress, a subsidiary of Zongteng Group, by adding a second Boeing 777-200 freighter under a long-term charter agreement.

Key Points: 
  • WHITE PLAINS, N.Y., March 28, 2024 (GLOBE NEWSWIRE) -- Atlas Air Inc., a subsidiary of Atlas Air Worldwide Holdings, Inc., a leading global provider of outsourced aviation logistics, today announced the expansion of its strategic partnership with YunExpress, a subsidiary of Zongteng Group, by adding a second Boeing 777-200 freighter under a long-term charter agreement.
  • Deepening the successful relationship between Atlas and YunExpress, this second 777 freighter will enter service for YunExpress in April and operate six weekly routes between China and the United States.
  • The new flying will enhance YunExpress’ international logistics network and help it serve the increasing demand for cross-border e-Commerce shipping from China.
  • "We are delighted to expand our strategic and long-term partnership with YunExpress," said Michael Steen, Chief Executive Officer, Atlas Air Worldwide.

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Retrieved on: 
Thursday, March 28, 2024
Brussels Stock Exchange, Sale, Atlas

Leuven, BELGIUM – March 28, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:

Key Points: 
  • Leuven, BELGIUM – March 28, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:
    Oxurion received a transparency notification on March 27, 2024, from Atlas Special Opportunities, LLC indicating that as of March 19, 2024, it held 0 (zero) shares of the then outstanding 5,753,951,723 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities.
  • See Annex 1.

RC Show 2024 Release New & Innovative Product Showcase

Retrieved on: 
Wednesday, March 27, 2024
Cooking, LFC, PFAS, Milk, Pineapple, Enercare Centre, Carbon, Wine, Pea, Restaurant, Creativity, Marketing, Automation, Red meat, Ginger, Drink, Miski, Hormone, VKD, Atlas, Freezing, Notch, Woman, Mouth, Safety, Interim, Cholesterol, Sambucus, Breakfast, Food, Rejuvenation, Taste, Bison, Coffee, RC, Plant, Food safety, Advertising, Farmer, Growth, ServiceNow, SoFi, Environment, Agave, Robotics, Water, Billio, MEIKO, AMT, Genetically modified organism, Tractor

Since 2010, KEENON Robotics , driven by its slogan "Keen on robots, keen on the future," has led the robotics sector.

Key Points: 
  • Since 2010, KEENON Robotics , driven by its slogan "Keen on robots, keen on the future," has led the robotics sector.
  • With a comprehensive range including advertising, delivery, hotel, and the latest addition, cleaning robots, they cater to diverse commercial needs.
  • Diversey Canada Inc. has been a pivotal player in increasing operational efficiency for the industry and that continues in 2024.
  • You will find more of these innovative products and solutions all under one roof at RC Show 2024, taking place April 8-10, where the industry will come together, be inspired and learn how to LEVEL UP!

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas - Amended version

Retrieved on: 
Wednesday, March 27, 2024
EUR, Brussels Stock Exchange, Exercise, Atlas, Capital commitment, Capital, Disclosure, Therapy, USD, Subscription business model, Consultant, Security (finance)

Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion.
  • Following completion of capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 9,014,821,287 outstanding ordinary shares carrying voting rights (compared to 7,384,386,505 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas

Retrieved on: 
Tuesday, March 26, 2024
EUR, Brussels Stock Exchange, Exercise, Atlas, Capital commitment, Capital, Disclosure, Therapy, USD, Subscription business model, Consultant, Security (finance)

Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion.
  • Following completion of capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 9,014,821,287 outstanding ordinary shares carrying voting rights (compared to 7,384,386,505 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Enterprise Receives Deepwater Port License for Spot Project

Retrieved on: 
Tuesday, April 9, 2024
Other Manufacturing, Other Energy, Chemicals, Plastics, Utilities, Oil, Gas, Manufacturing, Energy, Other Natural Resources, Natural Resources, MARAD, Partner, Corps, Employment, Natural gas, Documentation, Project, Transport, United States Coast Guard, Engineer, Security (finance), United, Risk, Accident, EPD, Water, Ship, DWP, SPOT, Department of transportation, NGL, Atlas

Enterprise Products Partners L.P. (NYSE: EPD) (“Enterprise”) today announced that it has received the deepwater port license for the Sea Port Oil Terminal (“SPOT”) from the United States Maritime Administration (“MARAD”), an agency within the federal Department of Transportation.

Key Points: 
  • Enterprise Products Partners L.P. (NYSE: EPD) (“Enterprise”) today announced that it has received the deepwater port license for the Sea Port Oil Terminal (“SPOT”) from the United States Maritime Administration (“MARAD”), an agency within the federal Department of Transportation.
  • The license enables Enterprise to move forward to the next step in developing the offshore terminal capable of loading 2 million barrels per day (“BPD”) of crude oil.
  • “I would like to congratulate the entire Enterprise team, which demonstrated outstanding technical skills, dedication and perseverance over the past five years, allowing us to receive this license,” said A.J.
  • The SPOT platform would also serve as a reef, supporting marine life.”
    MARAD and U.S. Coast Guard led the comprehensive, four-year environmental review of this project.